Moleculer genetic study of beta-micoseminoprotein in the prostage gland.

1.我们用荧光原位杂交技术将人β -微精原蛋白（β - msp）基因定位在10q11.2上，数据显示该基因位于先前确定的loh区域（10p和10q24*qter）之外。在单链构象多态性分析（SSCP）的突变分析中，40份癌组织样本未检测到异常条带。我们使用非放射性原位杂交和免疫组织化学分析了104例未经治疗的前列腺癌患者活检标本中β - msp mRNA及其蛋白的表达。104份标本中，β - msp mRNA阳性72份（69.2%），β - msp阴性96份（92.3%）。我们的研究结果显示，与良性前列腺组织相比，β - msp在前列腺癌组织中的表达水平较低，这一现象可能主要是由于β - msp mrna水平降低所致。为了评估β - msp mRNA表达和三个可能的预后因素（患者年龄、临床分期和组织学分级）对内分泌治疗进展时间的影响，采用Cox比例风险回归模型进行生存分析。D期患者的多因素分析显示，β - msp mRNA表达是内分泌治疗下病情进展的唯一显著预后指标（p=0.0034）。表达β - msp转录物的细胞的存在可能是潜在侵袭性前列腺癌的新指标。为了评估β - msp作为前列腺癌肿瘤标志物的有效性，我们测量了42例非转移性前列腺癌放疗前患者的结合和游离血清β - msp水平。肿瘤分期、分级和游离β - msp水平对治疗结果无显著预测作用。单因素分析显示，预处理PSA和结合/游离β - msp比值是放疗后复发的显著预测因子。除PSA外，β - msp可能对接受非转移性前列腺癌放疗的患者具有预后价值。少

1.We assigned the human beta-microseminoprotein (beta-MSP) gene to 10q11.2 with fluorescence in situ hybridization, and the data has shown that the gene is outside the previously identified LOH-regions (10p and 10q24*qter).2.In mutation analysis by single-strand conformational polymorphism analysis (SSCP), no aberrant bands were detected in 40 cancerous tissue samples analyzed.3.We analyzed the expression of both beta-MSP mRNA and its protein in biopsy specimens from 104 patients with untreated prostate cancer using both nonradioactive in situ hybridization and immunohistochemistry. Of the 104 specimens, 72 and 96 were negative for beta-MSP mRNA (69.2%) and beta-MSP (92.3%), respectively. Our results showed a lower level of expression of beta-MSP in prostate cancer tissue, compared with benign prostate tissue, and that this phenomenon may be mainly due to the presence of reduced levels of beta-MSP mRNA.4.To estimate the influence of beta-MSP mRNA expression and three possible prognosti … More c factors, i.e. , patient age, clinical stage and histological grade, on time to progression under endocrine therapy, survival analyzes were performed in Cox's proportional hazards regression model. Multivariate analysis of patients with stage D disease showed that beta-MSP mRNA expression was the only significant prognostic indicator for progression under endocrine therapy (p=0.0034). The presence of cells that express the beta-MSP transcript may be a novel indicator of potentially aggressive prostate cancers.5.To evaluate the usefulness of beta-MSP as a tumor marker for prostate cancer, we measured bound and free serum beta-MSP levels in 42 patients with non-metastatic prostate cancer preradiotherapy. Tumor stage, grade and free beta-MSP levels were not significant predictors of treatment outcome. Pretreatment PSA and the ratio of bound/free beta-MSP were significant predictors of relapse post radiotherapy on univariate analysis. beta-MSP in addition to PSA may be of prognostic value for patients receiving radiotherapy for non-metastatic prostate cancer. Less